|1.||Brines, Michael: 36 articles (01/2014 - 01/2002)|
|2.||Gassmann, Max: 34 articles (12/2015 - 07/2002)|
|3.||Cerami, Anthony: 33 articles (01/2014 - 01/2002)|
|4.||Casadevall, Nicole: 31 articles (03/2015 - 01/2002)|
|5.||van Veldhuisen, Dirk J: 31 articles (01/2015 - 02/2004)|
|6.||Prchal, Josef T: 26 articles (11/2014 - 08/2002)|
|7.||Ehrenreich, Hannelore: 24 articles (08/2015 - 08/2002)|
|8.||van Gilst, Wiek H: 23 articles (04/2011 - 02/2004)|
|9.||Voors, Adriaan A: 22 articles (01/2015 - 02/2004)|
|10.||Ghezzi, Pietro: 22 articles (01/2013 - 01/2002)|
05/01/2001 - "The most promising results have been noted in the treatment of erythropoietin-resistant anemia. "
09/04/1991 - "[Erythropoietin is highly effective in renal anemia but should be prescribed with caution]."
02/01/2007 - "Recombinant human erythropoietin (rhEpo) has proven to be remarkably safe and effective for treatment of anemias, primarily those secondary to renal disease and malignancy. "
01/01/2006 - "The only proven effective prevention of RBV-induced anemia is the concomitant administration of erythropoietin. "
05/01/1997 - "Recombinant human erythropoietin (rHuEPO) is used extensively in anemic patients on dialysis and other patients and is regarded as very safe and effective in the management of anemia in these patients. "
|2.||Chronic Kidney Failure (Chronic Renal Failure)
06/01/1996 - "The availability of recombinant human erythropoietin (rhuEPO) has dramatically improved the care of children with chronic renal failure (CRF). "
02/28/1985 - "Highly purified erythropoietin may be useful in the treatment of various forms of anaemia, particularly in chronic renal failure. "
01/01/1988 - "We conclude that recombinant human erythropoietin is very effective in treating the anaemia of end-stage renal failure on haemodialysis. "
06/01/2003 - "Anaemia correction with recombinant human erythropoietin (rh-EPO, epoetin) in end-stage renal disease (ESRD) patients has been associated with improved survival and quality of life, as well as lower overall treatment costs. "
04/01/1995 - "Epoetin (recombinant human erythropoietin) is now a widely available though expensive treatment for the anaemia of chronic renal failure, and is effective in more than 95% of patients. "
08/01/1998 - "The anaemia associated with cancer can be effectively treated with recombinant human erythropoietin (rHuEpo) in about 60% of the patients. "
07/01/1995 - "Recombinant human erythropoietin (r-Hu-EPO) is known to be effective in untreated cancer patients. "
05/01/2012 - "This novel long-acting erythropoietin derivative may have an advantage to inhibit tumor growth while preserving hematopoietic and tissue-protective effects."
01/01/2005 - "The purpose of this prospective study was to investigate the efficacy of preoperative administration of recombinant human erythropoietin in patients with gynecological cancer. "
01/01/2014 - "Several studies on the use of erythropoietin (Epo) to treat anaemia in patients undergoing cancer treatment have shown adverse effects on tumour control and survival. "
11/01/2007 - "Congeners of erythropoietin or EPO itself may be beneficial in protecting the heart against injury induced by ischemia thereby favorably modifying infarct size. "
03/01/2010 - "Erythropoietin augments the efficacy of therapeutic angiogenesis induced by allogenic bone marrow stromal cells in a rat model of limb ischemia."
01/01/2013 - "This study shows short-term protective efficacy of erythropoietin on rat testicular injury after ischemia/reperfusion."
08/01/2011 - "These conditions were used to study the potential tissue-protective effects of erythropoietin (EPO) in C2C12 myotubes exposed to ischemia. "
09/01/2007 - "Previous studies have shown that erythropoietin (EPO) has protective effects against ischemia/reperfusion (I/R) injury in several tissues. "
|5.||Myelodysplastic Syndromes (Myelodysplastic Syndrome)
01/01/1995 - "Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies."
09/01/2011 - "We investigated the efficacy of alpha recombinant human erythropoietin (α-rHuEPO) administered as single agent to 133 patients affected by myelodysplastic syndromes referring to our Institution in the last 10 years. "
08/01/1991 - "The clearance of a single i.v. bolus of recombinant human erythropoietin from the serum of patients with myelodysplastic syndromes and its effects on erythropoiesis."
06/01/2006 - "An open-label, phase II non-randomised trial was conducted with darbepoetin (DAR), an erythropoiesis-stimulating factor with prolonged half-life, at a weekly dose of 300 mug subcutaneously in 62 anaemic patients with myelodysplastic syndrome (MDS) with an endogenous erythropoietin (EPO) level <500 mU/ml. Most of the patients were classified as low or intermediate 1 according to the International Prognostic Scoring System. "
11/01/2004 - "[A study of erythropoietin use for myelodysplastic syndrome]."
|3.||Epoetin Alfa (Epogen)
|4.||Granulocyte Colony-Stimulating Factor (G-CSF)
|6.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|7.||darbepoetin alfa (Aranesp)
|9.||Nitric Oxide (Nitrogen Monoxide)
|1.||Renal Dialysis (Hemodialysis)
|2.||Drug Therapy (Chemotherapy)
|3.||Blood Transfusion (Blood Transfusions)
|5.||Transplantation (Transplant Recipients)